204387-55-3

Basic information

• Product Name: (R)-2-Methylpyrrolidine tosylate
• Synonyms: (R)-2-METHYL-PYRROLIDINE TOSYLATE;(R)-2-Methylpyrrolidine 4-methylphenylsulphonate;(2R)-2-Methylpyrrolidine toluene-4-sulphonate;(R)-2-Methylpyrrolidine p-toluenesulfonate, 97%;(2R)-2-Methylpyrrolidine tosylate;(R)-2-Methylpyrrolidine 4-methylbenzenesulfonate;(2R)-2-Methylpyrrolidine toluene-4-sulfonate
• CAS NO: 204387-55-3
• Molecular Formula: C12H19NO3S
• Molecular Weight: 257.35
• Product Categories: Heterocyclic Series
• Mol File: 204387-55-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 423.9 °C at 760 mmHg
• Flash Point: 210.2 °C
• Appearance: /
• Vapor Pressure: 6.09E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-Methylpyrrolidine tosylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Methylpyrrolidine tosylate(204387-55-3)
• EPA Substance Registry System: (R)-2-Methylpyrrolidine tosylate(204387-55-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 204387-55-3(Hazardous Substances Data)

Usage

General Description

"(R)-2-Methylpyrrolidine tosylate" is a chemical compound noted for its role in organic synthesis. It's a specialized reagent used in research laboratories. This molecule contains a pyrrolidine ring, which is a five-membered ring with nitrogen as one of the atoms, that is substituted with a methyl group. The term "(R)" signifies the specific spatial arrangement of these atoms, indicating that this molecule is one of two possible mirror-image forms (enantiomers), while "tosylate" suggests the presence of a tosylate group, known for its good leaving properties during chemical reactions. Its precise role and behavior would depend on the specific reaction and conditions.

InChI:InChI=1/C7H8O3S.C5H11N/c1-6-2-4-7(5-3-6)11(8,9)10;1-5-3-2-4-6-5/h2-5H,1H3,(H,8,9,10);5-6H,2-4H2,1H3/t;5-/m.1/s1

Upstream product

• 59378-81-3 1-(tert-butoxycarbonyl)prolin-2R-ol 
• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 132482-10-1 (R)-1-<(1,1-dimethylethoxy)carbonyl>-2-pyrrolidinemethanolmethanesulfonate 
• 137496-71-0 2-methylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 104-15-4 toluene-4-sulfonic acid 
• 765-38-8 (S)-2-methylpyrrolidine 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 132482-09-8 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}-pyrrolidine-1-carboxylate 
• 157007-54-0 2-(R)-methylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 765-38-8 (R)-(-)-2-methylpyrrolidine 

Relevant articles and documents

Synthesis and evaluation of in vivo anti-hypothermic effect of all stereoisomers of the thyrotropin-releasing hormone mimetic: Rovatirelin Hydrate

We discovered the orally active thyrotropin-releasing hormone (TRH) mimetic: (4S,5S)-5-methyl-N-{(2S)-1-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide 1 (rovatirelin). The central nervous system (CNS) effect of rovatirelin after intravenous (iv) administration is 100-fold higher than that of TRH. As 1 has four asymmetric carbons in its molecule, there are 16 stereoisomers. We synthesized and evaluated the anti-hypothermic effect of all stereoisomers of 1, which has the (4S),(5S),(2S),(2R) configuration from the N-terminus to the C-terminus, in order to clarify the structure?activity relationship (SAR) of stereoisomers. The (4R),(5R),(2R),(2S)-isomer 16 did not show any anti-hypothermic effect. Only the (4S),(5S),(2S),(2S)-isomer 10, which has the (2S)-2-methylpyrrolidine moiety at the C-terminus showed the anti-hypothermic effect similar to 1. Stereoisomers, which have the (5R) configuration of the oxazolidinone at the N-terminus and the (2R) configuration at the middle-part, showed a much lower anti-hypothermic effect than that of 1. On the other hand, stereoisomers, which have the (4R) configuration of the oxazolidinone at the N-terminus or the (2S) configuration of the C-terminus, have little influence on the anti-hypothermic effect.

Peptide derivatives having thiazolyl-alanine residue

A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.